Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rank in Stocks #7131
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Share Price
$40.39
Last synced: 2023-08-18
Market Cap
$1.70B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Chinook Therapeutics, Inc. (KDNY)

Category

Stock split history for Chinook Therapeutics, Inc. (KDNY)
Chinook Therapeutics, Inc. stock (symbol: KDNY) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 28, 2026.
One KDNY share bought prior to Aug 28, 2026 would equal to 0 KDNY shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH